Business Context and Reporting Period
Bioatla, Inc. (BCAB) is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers. This Form 10-Q covers the quarterly period ended June 30, 2026. The company is currently exploring strategic options to maximize shareholder value, including asset sales or partnerships, and has implemented a 70% workforce reduction. Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the issuance date due to insufficient cash to fund operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Balance Sheet June 30, 2026 |
|---|---|---|---|
| Collaboration Revenue | $6,500 | $6,500 | N/A |
| Net Income (Loss) | $452 | $(5,892) | N/A |
| Operating Expenses | $6,273 | $15,581 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,544 |
| Total Liabilities | N/A | N/A | $45,742 |
| Accumulated Deficit | N/A | N/A | $(551,538) |
Key Notes:
- Revenue: The $6.5 million revenue recognized in Q2 2026 stems entirely from a First Amendment to a license agreement with Context Therapeutics Inc., which settled future milestone and royalty obligations.
- Profitability: The company reported a net income of $0.5 million for the quarter, driven by the revenue recognition and a $0.2 million gain on warrant liability, offsetting operating expenses. However, the six-month period resulted in a net loss of $5.9 million.
- Liquidity: Cash balances dropped from $7.1 million at year-end 2025 to $1.5 million at June 30, 2026.
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased from $0 in the prior year periods to $6.5 million, solely due to the Context Therapeutics amendment.
- Expense Reduction: Total operating expenses decreased significantly year-over-year.
- R&D Expenses: Dropped from $13.7 million (Q2 2025) to $3.3 million (Q2 2026), a decrease of $10.3 million. This was driven by the completion of Phase 2 trials for three candidates and the 70% workforce reduction.
- G&A Expenses: Decreased from $5.0 million to $2.9 million, primarily due to personnel reductions and lower professional fees.
- Share Consolidation: On April 6, 2026, the company executed a 1-for-50 share consolidation. All historical share and per-share data have been retroactively adjusted.
- Warrant Liability: The fair value of the warrant liability decreased from $3.5 million (Dec 31, 2025) to $0.6 million (June 30, 2026), resulting in a non-cash gain of $2.9 million for the six-month period.
Outlook, Risks, and Contingencies
- Going Concern: The company explicitly states that its current cash of $1.5 million is insufficient to fund operations for the next 12 months. It relies on the Standby Equity Purchase Agreement (SEPA) with Yorkville (up to $15 million available), strategic transactions, or additional financing.
- Strategic Process: The company is evaluating strategic options including asset sales. Enrollment in the Phase 1 study of BA3182 has been paused while treatment and follow-up continue.
- Nasdaq Compliance: The company is currently not in compliance with Nasdaq listing requirements (Minimum Bid Price and Stockholders' Equity). A review by the Nasdaq Listing Council is ongoing; failure to regain compliance could result in delisting.
- Unusual Items:
- Context Amendment: A $6.5 million payment received from Context Therapeutics was recognized as revenue, satisfying all future obligations under that agreement.
- PPA Conversion: Pre-Paid Advance Agreements (PPAs) totaling $7.5 million were fully converted into common stock in Q1 2026, eliminating the associated liability.
Investor Verification Checklist
- Cash Runway: Verify the exact timeline for cash depletion given the $1.5 million balance and ongoing burn rate.
- Strategic Transaction Status: Monitor for updates on the formal process to explore strategic options (asset sales, partnerships) and whether a definitive agreement is reached.
- Nasdaq Listing Status: Confirm the outcome of the Nasdaq Listing Council review regarding delisting risks.
- SEPA Utilization: Track the utilization of the $15 million Standby Equity Purchase Agreement with Yorkville to determine if it will be sufficient to bridge funding gaps.
- Related Party Transactions: Review the terms of the Context Therapeutics amendment and the Himalaya Therapeutics agreement for potential conflicts of interest or future payment obligations.